P-GEMOX (pegaspargase + gemcitabine + oxaliplatin) for NK/T-cell nasal lymphoma

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-L-ASPARAGINASE` `DRUG-GEMCITABINE` `DRUG-OXALIPLATIN`

ID	`REG-P-GEMOX-NK-T`
Type	Regimen
Status	reviewed 2026-04-27 \| pending_clinical_signoff
Diseases	None declared
Sources	`SRC-ESMO-PTCL-2024` `SRC-NCCN-BCELL-2025`

Notes

Wang 2013 (Leukemia) — P-GEMOX in r/r NK/T-cell lymphoma ORR ~80%, CR ~50%; comparable to SMILE with less toxicity. Asparaginase remains essential for activity (P-glycoprotein-bypass mechanism shared with SMILE). For localized stage I/II — concurrent CRT with RT 50 Gy + 2-3 cycles. DDGP (dexamethasone + cisplatin + gemcitabine + pegaspargase) is a related modified regimen with similar efficacy.

Used By

Indication

IND-NK-T-NASAL-1L-P-GEMOX - IND-NK-T-NASAL-1L-P-GEMOX